KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) EBT (2017 - 2025)

Twist Bioscience (TWST) has disclosed EBT for 9 consecutive years, with -$30.3 million as the latest value for Q4 2025.

  • Quarterly EBT rose 3.95% to -$30.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$75.7 million through Dec 2025, up 61.53% year-over-year, with the annual reading at -$77.0 million for FY2025, 63.03% up from the prior year.
  • EBT for Q4 2025 was -$30.3 million at Twist Bioscience, down from -$26.9 million in the prior quarter.
  • The five-year high for EBT was $20.6 million in Q2 2025, with the low at -$85.4 million in Q2 2024.
  • Average EBT over 5 years is -$43.4 million, with a median of -$42.7 million recorded in 2021.
  • The sharpest move saw EBT crashed 70.35% in 2021, then skyrocketed 124.11% in 2025.
  • Over 5 years, EBT stood at -$56.0 million in 2021, then grew by 25.41% to -$41.7 million in 2022, then decreased by 2.73% to -$42.9 million in 2023, then increased by 26.56% to -$31.5 million in 2024, then rose by 3.95% to -$30.3 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$30.3 million, -$26.9 million, and $20.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.